Pacira | PCRX - Sales Revenues


Pacira reported $177M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Assertio Holdings USD 29.2M 1.92M Sep/2024
Astellas Pharma JPY 537.93B 33.28B Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
J&J USD 24.1B 500M Mar/2026
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novo Nordisk DKK 96.82B 17.68B Mar/2026
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026
Xoma USD 25K 5M Sep/2024
Zoetis USD 2.3B 100M Mar/2026